Rituxan Maintenance Prolongs Response Length in Low Grade NHL

German researchers have reported that Rituxan(R) (rituximab) maintenance prolongs response duration in patients with relapsed follicular and mantle cell lymphomas receiving induction chemotherapy with or without Rituxan. The details of this randomized trial were reported at the 2005 annual meeting of the American Society of Clinical Oncology, May 13-17 in Orlando, Florida.

The data suggests that Rituxan added to induction chemotherapy followed by Rituxan maintenance prolongs survival in patients with low-grade lymphoma. Full Article

LymphomaInfo Social